Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Carson

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Circulation|February 11, 2009
Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trialInder S Anand, Peter Carson, Elizabeth Galle, et al.
JACC. Heart Failure|March 7, 2023
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced TrialPeter Carson, John R Teerlink, Michel Komajda, et al.
Journal of Cardiac Failure|August 30, 2011
Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureWilliam T Abraham, Koonlawee Nademanee, Kent Volosin, et al.
Circulation|August 30, 2021
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved TrialMilton Packer, Javed Butler, Faiez Zannad, et al.
JACC. Heart Failure|February 3, 2025
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved TrialPeter Carson, John R Teerlink, Michel Komajda, et al.
American Heart Journal|February 15, 2011
A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureAlan Kadish, Koonlawee Nademanee, Kent Volosin, et al.
Circulation|October 21, 2020
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced TrialMilton Packer, Stefan D Anker, Javed Butler, et al.
The American Journal of Medicine|January 3, 2015
Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart FailureVikas Bhatia, Navkaranbir S Bajaj, Kumar Sanam, et al.
American Heart Journal|May 4, 2010
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) programChristopher M O'Connor, Alan B Miller, John E A Blair, et al.
JACC. Heart Failure|May 11, 2020
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical TrialsJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Circulation|February 11, 2009
Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trialInder S Anand, Peter Carson, Elizabeth Galle, et al.
JACC. Heart Failure|March 7, 2023
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced TrialPeter Carson, John R Teerlink, Michel Komajda, et al.
Journal of Cardiac Failure|August 30, 2011
Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureWilliam T Abraham, Koonlawee Nademanee, Kent Volosin, et al.
Circulation|August 30, 2021
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved TrialMilton Packer, Javed Butler, Faiez Zannad, et al.
JACC. Heart Failure|February 3, 2025
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved TrialPeter Carson, John R Teerlink, Michel Komajda, et al.
American Heart Journal|February 15, 2011
A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureAlan Kadish, Koonlawee Nademanee, Kent Volosin, et al.
Circulation|October 21, 2020
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced TrialMilton Packer, Stefan D Anker, Javed Butler, et al.
The American Journal of Medicine|January 3, 2015
Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart FailureVikas Bhatia, Navkaranbir S Bajaj, Kumar Sanam, et al.
American Heart Journal|May 4, 2010
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) programChristopher M O'Connor, Alan B Miller, John E A Blair, et al.
JACC. Heart Failure|May 11, 2020
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical TrialsJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 5